Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease
and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …

Although complex inflammatory-like alterations are observed around the amyloid plaques of
Alzheimer's disease (AD), little is known about the molecular changes and cellular …

Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability
development and interrupts neurocognitive function. This neuropathological condition is …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …